A challenging diagnosis of hepatosplenic T cell lymphoma in a 10-year-old child.

the potential to escalate to a maximum of 25 mg bid. However, in contrast to decitabine, greater caution is necessary when combined with intensive cytotoxic chemotherapy. Thus, further research is needed to determine the appropriate dosing. In summary, our case highlights that the combination of ruxolitinib and AML-style cytotoxic chemotherapy is an attractive option for older patients with post-MPN AML. Given the heterogeneity of this population and the lack of treatment options, further exploration of the role of ruxolitinib in combination with cytotoxic chemotherapy is required.